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Mutations in both copies (homozygous or compound heterozygous) of the gene encoding
the lysosomal enzyme glucocerebrosidase, which cleaves the glycolipid glucocerebroside
into glucose and ceramide cause Gaucher disease. However, multiple independent stud-
ies have also reported an association between GBA mutations and Parkinsonism with
an increased frequency of heterozygous GBA mutations in various cohorts of patients
with parkinsonism and other Lewy body disorders. Furthermore, GBA mutation carriers
exhibit diverse parkinsonian phenotypes and present a diffuse pattern of Lewy body dis-
tribution in the cerebral cortex. This review provides an overview of the genetic basis
for this association in various diseases with dysfunction of the central nervous system in
which affected individuals developed Parkinsonian symptoms.The emerging clinical, patho-
logical, and genetic studies in neuronal synucleinopathies suggest a common underlying
mechanism in the etiology of these neurodegenerative disorders.
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INTRODUCTION
GAUCHER DISEASE
Mutations in the glucocerebrosidase gene (OMIM #606463),
which encodes the lysosomal enzyme glucocerebrosidase, which
breaks down the glycolipid glucocerebroside (also called glucosyl-
ceramide) into glucose and ceramide, result in Gaucher disease
(GD; Brady et al., 1965). This is the most common lysosomal
storage disorder (LSD) and follows an autosomal recessive mode
of inheritance. The accumulation of glucosylceramide primarily
occurs in cells of the reticulo endothelial system. The classic cellu-
lar hallmark of Gaucher patients is the characteristic morphology
of theirmacrophageswith a“wrinkled tissue paper”appearance on
cytoplasm, which contains lysosomal inclusion bodies, referred as
Gaucher cells (Westbroek et al., 2011). These macrophages accu-
mulate in the liver, spleen, and bone marrow, and patients can
present with organomegaly (Beutler and Grabowski, 2001; Sidran-
sky,2004). PatientswithGDcanpresentwith a broad range of phe-
notype and the spectrum of the disease correlates, at least in part,
with residual enzyme activity (Cox and Schoﬁeld, 1997). Based on
the age at onset andneurologicalmanifestations, the disease is clas-
siﬁed into three subtypes (type 1, OMIM #230800; type 2, OMIM
#230900; and type 3, OMIM #2301000; Velayati et al., 2010). The
most common phenotype is non-neuronopathic type 1, some-
times referred as “adult Gaucher disease,” although it can affect
individuals of all ages. There is enough residual enzyme activity to
prevent subtract storage in other cells rather than macrophages.
Type 1 GD is relatively common in all ethnic groups, it presents
the highest carrier frequency among Ashkenazi Jews population
of 1 in 15 and an incidence of about 1 in 1,000. Although type
1 disease is traditionally considered non-neuronopathic, a sub-
set of patients developed neurological alterations and subclinical
peripheral neuropathy (Capablo et al., 2008). Patients with neu-
ronopathic formsof the disease,presentwith either an acute course
(type 2) or subacute course (type 3). Type 2 phenotype is the most
severe form, often presenting in the ﬁrst 6months of life and the
complete deﬁciency in glucocerebrosidase activity result in glu-
cosylceramide accumulation in a variety of cell types, including
neurons, which leads to rapidly fatal consequences either prena-
tally or shortly after birth (Cox and Schoﬁeld, 1997; Sidransky,
2004). Elevations in brain glucosylsphingosine have been detected
in patients with neuronopathic GD, but not with type 1 (Orvisky
et al., 2002). Type 3 tends to progress more slowly than type 2
and usually appears in adolescence. Affected individuals may sur-
vive into their 30 years. While not limited to any particular ethnic
group, the largest group of patients with GD type 3 has been
reported from the province of Norrbotten in Sweden (Dahl et al.,
1990) and increased prevalence rates have also been reported in
Japan and Spain. Although the GBA genotype plays a role in
determining the type of GD, genotype–phenotype correlations
are difﬁcult to be established, due to the enormous clinical vari-
ation concerning the disease manifestations, clinical course, and
response to therapy exhibited between patientswho share the same
genotype (Lachmann et al., 2004; Sidransky, 2004). Differences
are even observed among siblings and twins (Amato et al., 2004;
Lachmann et al., 2004).
GLUCOCEREBROSIDASE GENE (GBA)
The humanGBA gene is located on chromosome 1q21 and is com-
posed by 11 exons and 10 introns, spanning 7.6 kb of sequence.
A highly homologous pseudogene (GBAP) is located 16 kb down-
stream and is 5.7 kb in length (Horowitz et al., 1989). The presence
of this highly homologous pseudogene at the same locus, which
shares 96% exonic sequence homology explains the high number
of complex recombinant alleles between GBA and GBAP which
have been detected in several GD, Parkinson’s disease (PD), or
Lewy body dementia (LBD) patients (Hruska et al., 2008).
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To date, approximately 300 pathogenic mutations scattered
throughout the GBA gene have been reported and their frequency
varies signiﬁcantly according to the different ethnicity. For exam-
ple, the common c.1226A>G (N370S) allele is quite frequent
among patients of European, American, and Middle East origin
and it is not seen in Chinese and Japanese cohorts. Moreover,
this particular mutation accounts for approximately 70% of the
mutant alleles in an Ashkenazi Jewish subjects with type 1 GD
and with c.84dupG mutation accounts for about 10%. Therefore,
focusing the mutation analysis only to these two mutations in
Ashkenazi Jewish populations of GD type 1 could be considered a
cost-effective procedure. However to other non-Ashkenazi Jewish
populations, especially in patients with neuronopathic GD forms,
the whole gene sequencing is required for an accurate genotyping
(Hruska et al., 2008). Furthermore, to populations of European
origin, two mutations, N370S and L444P contribute to two-thirds
of the disease alleles found (Kaplan et al., 2006;Hruska et al., 2008).
The allelic distribution of these two prevalentmutant alleles can be
confused because many laboratories do not distinguish between
the point mutation c.1448T>C (L444P) and recombinant alleles
that include this mutation such as RecNciI (Hruska et al., 2008).
GAUCHER DISEASE AND PARKINSONISM
Clinical reports of patients with GD recognized a small subset of
patients who develop parkinsonian symptoms including tremor,
rigidity, and bradykinesia (Neudorfer et al., 1996;Machaczka et al.,
1999; Bembi et al., 2003). In themajority of these cases, the onset of
parkinsonian manifestations was noted in their 40 years, and cog-
nitive changes had also occurred (Tayebi et al., 2003). Postmortem
brain tissue of several of these subjects was examined, and Lewy
bodies appeared in cortical areas corresponding to Braak stages 5–
6, in addition to the classic PD pathology (Neumann et al., 2009).
The substantia nigra showed a marked loss of pigmented neurons
while numerous Lewy bodies were detected and were speciﬁcally
associated with brain regions affected by GD, including the CA4–
CA2 hippocampal regions (Wong et al., 2000, 2004). In order
to investigate the underlying dopaminergic dysfunction in GBA
mutation carriers with and without parkinsonism, Kono et al.
(2010) used positron emission tomography (PET) and demon-
strated presynaptic dopaminergic dysfunction in the GBA carriers
with parkinsonism identical to PD.
Moreover, a higher frequency of PD has also been reported
in relatives of patients with GD, many of whom were demon-
strated to harbor a heterozygous mutation in GBA. Families of
probands with GD were surveyed for the presence of PD among
obligate GBA carriers, and a higher rate of PD has been observed
compared to the putatively non-carriers cohort. These clinical
observations, strengthen the association between these two disor-
ders and provided evidence that mutant glucocerebrosidase, even
in heterozygosity may be a risk factor for the development of
parkinsonism (Goker-Alpan et al., 2004; Halperin et al., 2003).
Furthermore, a recent study was able to estimate the PD pene-
trance in GBA mutation carriers. The authors considered GBA as
a dominant causal gene with reduced penetrance which should
be taken into consideration for genetic counseling in relatives of
patients with GD and patients with GBA associated PD (Anheim
et al., 2012).
GBA MUTATIONS IN PD COHORTS
The clinical observations of GD patients and their relatives
prompted an examination of the GBA mutations among different
cohorts of PD worldwide. The ﬁrst description of the relationship
between alterations in the GBA and PD has reported alterations in
GBA in 12 (21%) autopsy samples of PDpatients. These alterations
were more frequent among the younger subjects. These included
eight with mutations (N370S, L444P,K198T, and R329C) and four
with probable polymorphisms (T369M and E326K; Lwin et al.,
2004). Subsequently, the sixGBA mutations (N370S,L444P,84GG,
IVS+ 1, V394L, and R496H) which are most common among
Ashkenazi Jews were screened for a clinic-based case series of 99
Ashkenazi patients with idiopathic PD and 1,543 healthy Ashke-
nazi Jews. Mutations were found in 31.3% of PD patients versus
6.2% of controls (P < 0.001). Once more, patients who were car-
riers of GBA mutations were younger than those who were not
carriers (Aharon-Peretz et al., 2004).
Since then, multiple studies were conducted, in which these
ﬁndings were replicated in various cohorts of PD patients with
different geographical or ethnical origins. These studies reported
higher GBA mutation frequencies among the Ashkenazi Jewish
PD population, which varied in different centers, between 10.7
and 31.3% contrasting,with the lowest carrier frequency reported,
2.3% in a series of Norwegian patients with PD versus 1.7% in
controls (Toft et al., 2006). To accurately ascertain the frequency
of GBA mutations in Europe, several European non-Ashkenazi
Jewish individuals with PD and ethnicity-matched controls were
screened and GBA alterations have been found in 6.1% of Por-
tuguese (Bras et al., 2009), 9.8% of Spanish (Setó-Salvia et al.,
2011), 4.2% British (Neumann et al., 2009), 4.7% of Greek (Kalin-
deri et al., 2009), 6.7% of French (Lesage et al., 2010), and 2.8%
of Italian (De Marco et al., 2008). Importantly, some of the pre-
vious studies have focused the mutation analysis only in the two
most common mutations, N370S and L444P, whereas some oth-
ers extended the mutations search to the entire coding region
of the gene. Overall, the deﬁnitive study on this topic was pub-
lished in 2009, when an international collaborative study of GBA
mutations in PD patients was undertaken by pooling data for indi-
vidual persons from 16 centers, in 12 countries, including 5,691
patients and 4,898 controls. The data collected demonstrated a
strong association between GBA mutations and PD. This ﬁnd-
ing was not exclusive to a speciﬁc ethnic group or a speciﬁc GBA
mutation. In addition, the age at onset of PD was found to be
signiﬁcantly lower among patients with GBA mutations as com-
pared with those without mutations (P < 0.001; Sidransky et al.,
2009).
Concordant results have been observed in familial PD cases. A
large comprehensive study of all GBA exons in one patient with
PD from each of 96 PD families selected, based on the family-
speciﬁc lod scores at the GBA locus revealed nine different variants
identiﬁed in 21 of the 96 PD cases (21.8%). These variants have
been further tested in 1,325 PD cases from 566 multiplex PD
families and in 359 controls and were present in 161 of these
patients (12.2%) versus 5.3% of controls (Nichols et al., 2009).
Similarly, a Japanese group identiﬁed eight multiplex PD families
with patients with PD heterozygous for pathogenic mutations in
GBA (Mitsui et al., 2009). Therefore, it is conceivable that GBA
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mutations underlie not only sporadic PD but also familial PD, and
are associated with signiﬁcantly earlier age at onset of disease.
GBA MUTATIONS IN OTHER SYNUCLEINOPATHIES
There is a line of evidence for the association of GBA mutations
with other synucleinopathies rather than PD, such as dementia
with Lewy bodies (DLB) and Lewy body variant Alzheimer disease
(LBV-AD) but not in multiple-system atrophy (MSA).
Initially, Goker-Alpan et al. (2006) performed full genotyp-
ing of GBA in DNA from brain samples of 75 autopsy cases with
pathologically conﬁrmed Lewy body disorders including 28 PD,35
cortical LBs (DLB or LBV-AD), and 12 MSA. Mutations in GBA
gene were identiﬁed in 4% of cases with PD, 23% of cortical LBs,
and none with MSA. A low frequency of GBA mutations, similar
between cases (0.9%) and controls (1.2%) was also reported in a
series of 108 British MSA pathologically conﬁrmed cases and 257
controls (Neumann et al., 2009). Similarly, two additional studies
did not identify GBA pathogenic mutations among MSA patients.
One of the studies involved the sequencing of GBA in 27MSAcases
(Nishioka et al., 2011) and in the other one, the two most common
mutations, L444P and N370S were tested in 66 MSA cases (Jam-
rozik et al., 2009). These data suggested a different mechanism
to the α-synuclein aggregation in MSA cases in which its prin-
cipal cellular target is the oligodendrocytes. The evolved concept
that MSA may not just be related to PD but also share traits with
the family of demyelinating disorders has been recently reviewed
(Wenning et al., 2008).
As with the ﬁrst study, an increased frequency of GBA muta-
tions has also been detected in 2 (3.5%) of 57 clinical DLB patients
of European Caucasian ancestry compared with control subjects
(0.4%; Mata et al., 2008). In this latter study, only the two muta-
tions, N370S and L444P were tested. Also, Farrer et al. (2009)
reported mutations in GBA in 6% of 50 brain samples from
subjects with pathologically conﬁrmed diffuse LBD. Conversely,
another study found GBA mutations in 28% (27 of 95) of patients
with primary pathological diagnoses of LB disorders, compared
with 10% (6 of 60) of cases with primary AD and 3% (1 of 32) of
control cases (Clark et al., 2009). In this latter study, the presence
of GBA mutations appeared to be related more to the presence
of cortical LBs than to LBs conﬁned to the subcortical regions.
Moreover, GBA mutations were also detected in 6.8% (4/59) of
cases with a pathological diagnosis of diffuse Lewy body disease.
Taken with previous studies, it appears that GBA mutations are
associated with a more diffuse pattern of Lewy body distribution
involving the cerebral cortex than the brainstem/limbic distribu-
tion observed in typical PD (Nishioka et al., 2011).Also Setó-Salvia
et al. (2011) reported more recently, 12% of LBD brains carrying
a mutated GBA allele.
GBA MUTATIONS AND COGNITIVE DECLINE
Given the distribution of Lewy bodies into the neocortical regions,
subsequently studies were conducted to rule out the inﬂuence
of GBA mutations in the clinical course of PD, including cogni-
tive decline and dementia. A prospectively evaluation at the NIH
Clinical Center with detailed neurological examinations reported
cognitive changes in half of the subjects (Goker-Alpan et al., 2008).
In addition, the clinical features of a British PD patient group who
carried GBA mutations comprised, an early-onset of the disease,
the presence of hallucinations in 45% (14/31) and symptoms of
cognitive decline or dementia in 48% (15/31) of the patients (Neu-
mann et al., 2009). The effect of GBA on susceptibility to dementia
was reinforced in Spanish PD patients with GBA mutations, in
which half of the patients developed dementia during the clinical
course of PD (Setó-Salvia et al., 2011).
OTHER LYSOSOMAL STORAGE DISORDERS AND PARKINSONISM
Glucocerebrosidase has been identiﬁed as a component of the
Lewy body’s inclusions in patients with GBA mutations (Goker-
Alpan et al., 2010) and it colocalized with lysosomal-associated
membraneprotein 1 (LAMP1)marker,which suggested an impair-
ment of the lysosomal activity in LB pathology. This observation
is supported by the emerging reports of PD across a range of LSDs.
Over two-thirds of LSDs involve central nervous system dysfunc-
tion (progressive cognitive and motor decline) whereas affected
individuals developed frequently parkinsonism with deposits of
α-synuclein in the brain and substantia nigra pathology (Shachar
et al., 2011; Schultz et al., 2011). For the ﬁrst time, it was
recently demonstrated accumulation of the α-synuclein in the
cortical tissue of two postmortem cases of Sanﬁlippo syndrome
(mucopolysaccharidosis type III, MPSIII; Winder-Rhodes et al.,
2012). MPSIII is an autosomal recessive neurodegenerative stor-
age disease caused by mutations in N -acetylglucosaminidase
(NAGLU ) gene. Additional case reports of LSDs have described
parkinsonism features among patients and in postmortem tis-
sues, Lewy body’s inclusions have been observed. Thus, patients
with GM1 gangliosidosis (caused by defective β-galactosidase
activity), GM2 gangliosidoses, including Tay–Sachs and Sand-
hoff diseases (caused by defective β-hexosaminidase activity) and
Fabry–Anderson disease (caused by the defective activity of α-
galactosidase) as well as some family members, developed various
PD symptoms including bradykinesia, rigidity, and resting tremor
(Argov and Navon, 1984; Inzelberg and Korczyn, 1994; Orimo
et al., 1994; Muthane et al., 2004; Roze et al., 2005).
Also relatives and patients with Niemann–Pick C disease
(caused by the defective activity of either NPC1 or NPC2) pre-
sented with parkinsonian tremor and an α-synucleinopathy in
human NPC brain was observed in the midbrain and amygdale of
a postmortem tissue (Saito et al., 2004).
Therefore, the link of PDandLSDs suggested a commonunder-
lying mechanism compromising the lysosomal and proteasomal
degrading systems, resulting to the α-synuclein pathology shared
by several of these disorders (Settembre et al., 2008). This asso-
ciation, as described above is not limited exclusively to changes
that occur in GD, such as changes in glucocerebrosidase activ-
ity or in glucosylceramide levels, but rather include changes that
might be common to a wide variety of LSDs. So it may be inter-
esting in a near future to investigate the frequency of mutations
in genes encoding lysosomal proteins in the patients who display
Parkinson’s symptoms.
GBA MUTATIONS AND CERAMIDE METABOLISM
Although GBA mutations and consequently glucocerebrosidase
deﬁciency show a clear and, potentially direct risk association
with α-synucleinopathies and PD, it was suggested that this link is
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due to its subtract accumulation, glucosylceramide excess, rather
than the decrease levels of its subproduct, ceramide. Several stud-
ies have been conducted and no evidence of ceramide deﬁciency
has been detected in patients with GD, even in those severely
affected. This ﬁnding supported the existence of a tightly regulated
ceramide levels resultant frommanydifferent degradative and syn-
thetic pathways. So, the link between GBA heterozygosity and PD
or other synucleinopathies may not be determined by ceramide
metabolism dysfunction. In fact, the use of inhibitors of the gluco-
cerebrosidase function has been shown to modulate α-synuclein
levels (Manning-Bog et al., 2009). In addition, the α-synuclein
aggregation and glucosylceramide accumulation occurred in a
chemically induced glucocerebrosidase deﬁciency. These stud-
ies demonstrated a relationship between glucosylceramide accu-
mulation and α-synuclein aggregates, and implicate glucosylce-
ramide accumulation as risk factor for the α-synucleinopathies
(Xu et al., 2010). Nevertheless, it was proposed that the abnor-
mal α-synuclein pathology presented in neurodegeneration with
brain iron accumulation 1 and 2 (NBAI-1, NBAI-2) caused by
mutations in the pantothenate kinase type 2 (PANK2) and phos-
pholipase A2, group VI (PLA2G6) genes, respectively, could be
connected to ceramide metabolism (Bras et al., 2008). However,
very recently, it was demonstrated that PLA2G6 mutations were
the second common genetic cause after PARK2 gene mutation
in cohorts of Chinese and Taiwanese young-onset parkinsonism
with Chinese ethnicity (Shi et al., 2011; Lu et al., 2012). Addition-
ally, the postmortem study on a series of patients with PLA2G6
mutations, demonstrated widespread α-synuclein positive Lewy
pathology particularly severe in the neocortex (Paisán-Ruiz et al.,
2012). Therefore, in order to rule out the pathogenic mechanism
by which, mutations in PLA2G6 gene cause PD, it will be interest-
ing to measure the ceramide levels in these early-onset PD patients
carrying mutations in the PLA2G6 gene.
POSSIBLE MECHANISMS LINK GBA AND PD AND
α-SYNUCLEINOPATHIES
GBA mutations act as a strong risk factor to α-synucleinopathies
and Parkinson disease interfering with the clearance of or pro-
mote the aggregation of α-synuclein. Mazzulli et al. (2011) have
shown that intracellular glucosylceramide levels control the for-
mation of soluble toxic α-synuclein assemblies in cultured neu-
rons and mouse and human brain, leading to neurodegeneration.
The elevation and formation of α-synuclein assemblies inhibits
the lysosomal activity of normal glucocerebrosidase in neurons
and idiopathic PD brain, resulting in additional glucosylceramide
accumulation and augmented α-synuclein oligomer formation.
This self-propagating positive feedback process, proceeds until
a pathogenic threshold is reached, resulting in neurodegenera-
tion (Mazzulli et al., 2011). The frequently reported lysosomal
proteolytic dysfunction in PD as well is in other LSDs is one of
the common mechanisms underlying the α-synuclein pathology
shared by various of these disorders (Shachar et al., 2011;Yap et al.,
2011). Indeed, the disruption of autophagy-lysosomal process has
been proposed as the mechanism by which LRRK2 mutations,
the gene responsible for the autosomal dominant forms of PD,
may exert its effects (Tong et al., 2010). The autophagy degrad-
ing pathway is considered the primary mechanism through which
α-synuclein is degraded and its impairment is reinforced by the
involvement of another gene associated with familial forms of PD,
ATP13A gene, which encodes a lysosomal ATPase responsible for
maintaining intralysosomal pH and suppresses α-synuclein toxic-
ity in C. elegans, yeast, and primary neuronal cultures (Gitler et al.,
2009). In addition, the dysfunction of the ubiquitin–proteasome
system also underlies many of these α-synucleinopathies. Again,
Parkin gene which has been associated mostly with the early-onset
PD recessive familial cases encodes the E3 ubiquitin ligase, and
is involved in the ubiquitination pathway of misfolded glucocere-
brosidase in dopaminergic neurons. The absence of normal parkin
leads to improper degradation of some of its subtracts, such as
α-synuclein and to their accumulation (Ron et al., 2010).
A distinct α-synuclein degraded pathway within lysosomes
is the chaperone mediated autophagy (CMA), whereas SNCA
mutants Ala53Thr and Ala30Pro bind to LAMP2A but fail to
translocate into the lysosomal lumen for breakdown (Cuervo et al.,
2004; Cullen et al., 2011). Subsequently, further CMA-mediated
degradation substrates are blocked, which contributes to their
accumulation (Westbroek et al., 2011). Likewise, defects in mito-
chondrial activity are reported in many of α-synucleinopathies
which results mainly in decrease levels of the ATP synthesis, caus-
ing the formation of free radicals leading to oxidative stress and
impairment of the membrane potential (Schapira, 2011). Several
studies have demonstrated the effect of PD causative genes also on
mitochondrial depolarization and their interference in the electron
transport chain (Schapira and Gegg, 2011).
Additionally, GBA haploinsufﬁciency alters the lipid metabo-
lism and composition of the cell membranes which is also consid-
ered a common impaired pathway in many of these disorders. The
helical binding of α-synuclein to lipid membranes prevents the
formation of ﬁbrillar protein structures. It has been demonstrated
that α-synuclein does bind to brain-derived glycosphingolipids
that contain glucosylceramide in their core. Therefore, deﬁciency
of glucocerebrosidase leads to the accumulation of its substrates
glucosylceramide and/or glucosylsphingosine and alter sphin-
golipid composition of the cell membranes, which may disrupt
the membrane binding of α-synuclein, enhancing its aggregation
in the cytoplasm (DePaolo et al., 2009).
In this article, an extensive literature review has documented
clinical, pathological, and genetic studies which have contributed
to our growing understanding of the involvement of the gluco-
cerebrosidase as a susceptibility factor to PD and other synucle-
inopathies. The rapid pace of investigation of the GBA function
has been stimulated by the identiﬁcation of mutations in this gene,
not only in GD patients, but also in sporadic and familial PD
cohorts as well as in different α-synucleinopathies. The clinical
and pathological studies have accompanied and complement the
genetic analysis of GBA gene in different patient’s cohorts, adding
a crucial value toward the delineation of the different molecular
pathways underlying the pathogenesis of these conditions. Curi-
ously, an attempt to integrate the differentmolecular pathways and
functions in a unique mechanism indicates a considerable over-
lap between them, suggesting interactions of pathological proteins
engaging common downstream pathways which is not only rele-
vant for the familial forms, but also to the more common sporadic
PD cases.
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